HALIFAX, Nova Scotia - Rapid diagnostic developer MedMira Inc. announced on November 17, 2026, that the U.S. Food and Drug Administration granted Breakthrough Device Designation to its Multiplo Complete Syphilis Antibody Test.
Instrument-Free Fingerstick Test Combines Two Measurements
Granted by the FDA's Center for Devices and Radiological Health, the test uses MedMira's patented Rapid Vertical Flow Technology to detect both treponemal and non-treponemal antibodies simultaneously from a single fingerstick whole-blood specimen. Unlike conventional laboratory workflows requiring multiple procedures and specialized equipment, the point-of-care test delivers rapid visual results designed for clinics and remote communities.
Advisory Pilot Invitation Supports U.S. Regulatory Path
While the Breakthrough Devices Program offers prioritized FDA interaction to speed development, it does not represent commercial marketing clearance. "The FDA's decision reinforces the potential significance of our technology and represents an important step as we advance our development program toward the U.S. market," MedMira CEO Hermes Chan said. Following the designation, the FDA's Total Product Life Cycle Advisory Program invited MedMira to apply for its pilot program to collaborate closely on U.S. clinical and regulatory strategy.


